DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

Phase 2

Terminated

Conditions: Non-Small Cell Lung Cancer, Head and Neck Cancer

Interventions: Drug: ponatinib

First Posted Date: 2013-01-07

Last Posted Date: 2014-12-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 3

Registration Number: NCT01761747

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

Phase 2

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Tacrolimus
Drug: Methotrexate
Drug: Bortezomib
Drug: Sirolimus

First Posted Date: 2012-12-21

Last Posted Date: 2017-07-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 138

Registration Number: NCT01754389

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 1 locations

INHERIT EGFR - Studying Germline EGFR Mutations

Active, not recruiting

Conditions: Lung Cancer

First Posted Date: 2012-12-21

Last Posted Date: 2024-03-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 121

Registration Number: NCT01754025

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Dendritic Cell Activating Scaffold in Melanoma

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: WDVAX

First Posted Date: 2012-12-20

Last Posted Date: 2024-01-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT01753089

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Ziv-aflibercept

First Posted Date: 2012-12-11

Last Posted Date: 2020-02-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 64

Registration Number: NCT01747551

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Phase 2

Terminated

Conditions: T-cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Etoposide
Drug: Prednisone
Drug: Filgrastim
Drug: Plerixafor
Procedure: Stem Cell Collection
Drug: Palifermin
Drug: Gemcitabine
Drug: Busulfan
Drug: Melphalan
Procedure: Stem Cell Transplant

First Posted Date: 2012-12-10

Last Posted Date: 2023-01-30

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 5

Registration Number: NCT01746173

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

BKM120+Abiraterone Acetate for Metastatic CRPC

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: BKM120
Drug: Abiraterone
Drug: Prednisone

First Posted Date: 2012-12-05

Last Posted Date: 2019-02-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 4

Registration Number: NCT01741753

Locations: 🇺🇸
Beth-Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Standard Dissemination
Behavioral: Capacity Enhancement

First Posted Date: 2012-12-04

Last Posted Date: 2019-06-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 348

Registration Number: NCT01740219

Locations: 🇺🇸
University of Massachusetts Boston, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Tufts University, Medford, Massachusetts, United States

Cabozantinib for Metastatic Triple Negative BrCa

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Cabozantinib

First Posted Date: 2012-11-30

Last Posted Date: 2016-12-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01738438

Locations: 🇺🇸
Dana-Farber Cancer Institute at Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cisplatin + RT for Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Radiation: Radiation Therapy
Drug: Cisplatin

First Posted Date: 2012-08-29

Last Posted Date: 2021-08-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT01674842

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber at Milford, Milford, Massachusetts, United States
🇺🇸
Dana Farber at South Shore Hospital, Weymouth, Massachusetts, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy